107. 若年性特発性関節炎 Juvenile idiopathic arthritis Clinical trials / Disease details

臨床試験数 : 447 / 薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146

diseases per page:

Showing 1 to 10 of 447 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04585711 (ClinicalTrials.gov)	May 2023	7/10/2020	Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis	Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis	Juvenile Idiopathic Arthritis;Rheumatoid Arthritis;Obesity	Drug: Etanercept Optimal dosing	Duke University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not yet recruiting	2 Years	65 Years	All	30	Phase 1	United States
2	NCT05609630 (ClinicalTrials.gov)	March 15, 2023	7/11/2022	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Ac ...	A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of U ...	Juvenile Idiopathic Arthritis	Drug: Upadacitinib;Drug: Tocilizumab	AbbVie	NULL	Not yet recruiting	1 Year	17 Years	All	90	Phase 3	NULL
3	EUCTR2022-003024-41-ES (EUCTR)	25/01/2023	25/11/2022	Apremilast study in children with active oral ulcers associated with Behçet's Disease or Juvenile Ps ...	A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of A ...	Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis MedDRA version: 21.1;Level: LL ...	Trade Name: Otezla Product Name: Apremilast 20 mg Product Code: AMG 407 INN or Proposed INN: Apremilast T ...	Amgen Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 3	France;Greece;Spain;Turkey;Israel;United Kingdom;Italy;Switzerland
4	NCT05534347 (ClinicalTrials.gov)	September 2022	6/9/2022	Angiogenic Biomarkers in Juvenile Idiopathic Arthritis	Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis	Juvenile Idiopathic Arthritis (JIA)	Biological: Blood sample;Biological: Joint puncture	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	16 Years	N/A	All	300		France
5	JPRN-jRCT2031220187	01/08/2022	07/07/2022	Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS ...	A Two-cohort, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerabilit ...	Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, SLE	Emapalumab iv infusion initial dose: 6 mg/kg Subsequent doses: 3 mg/kg	Nakaoku Takahiro	NULL	Recruiting	>= 6month old	<= 80age old	Both	2	Phase 2-3	Belgium;Canada;China;Czechia;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;Uni ...
6	JPRN-jRCT2031220222	01/07/2022	25/07/2022	Sobi.ANAKIN-303	A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of su ...	Systemic juvenile idiopathic arthritis(SJIA)., adult-onset Still's disease (AOSD)	- Pediatric and adult patients weighing >_ 50kg:Anakinra100mg/day - Pediatric and adult patients weig ...	Takeshi KUROSAWA	NULL	Recruiting	>= 8month old	Not applicable	Both	15	Phase 3	Japan
7	NCT05540743 (ClinicalTrials.gov)	July 1, 2022	12/9/2022	Biologic Therapy in Pediatric JIA Uveitis	The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Coh ...	Juvenile Idiopathic Arthritis Associated Uveitis	Drug: biologic DMARDs	Kasr El Aini Hospital	NULL	Active, not recruiting	3 Months	16 Years	All	250	Phase 4	Egypt
8	EUCTR2011-004915-22-NL (EUCTR)	17/05/2022	05/02/2021	A Long-Term, Open-Label, Study for Treatment of JIA	A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITI ...	JUVENILE IDIOPATHIC ARTHRITIS(JIA) MedDRA version: 23.1;Level: PT;Classification code 10059176;Term: ...	Trade Name: XELJANZ Product Code: CP -690,550-10 INN or Proposed INN: Tofacitinib Product Code: CP -690,5 ...	Pfizer Inc, 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	340	Phase 2;Phase 3	United States;Slovakia;Spain;Costa Rica;Ukraine;Turkey;Chile;Israel;Russian Federation;United Kingdo ...
9	EUCTR2019-002788-88-GR (EUCTR)	14/04/2022	01/02/2022	Apremilast Study in Children with Active Juvenile Psoriatic Arthritis	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evalua ...	Juvenile psoriatic arthritis MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Syst ...	Trade Name: Otezla Product Name: Apremilast 10 mg Product Code: AMG-407 INN or Proposed INN: Apremilast T ...	Amgen Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 3	France;Greece;Poland;Belgium;Austria;Netherlands;Italy
10	EUCTR2017-002018-29-HU (EUCTR)	04/01/2022	25/10/2021	Efficacy and Safety Study Of Tofacitinib in Pediatric sJIA Population	EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENIL ...	Systemic Juvenile Idiopathic Arthritis(sJIA);Therapeutic area: Diseases [C] - Immune System Diseases ...	Product Name: Tofacitinib citrate Product Code: CP -690,550-10 INN or Proposed INN: tofacitinib Other des ...	Pfizer Inc. 235 East 42nd Street, New York, New York 10017	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	United States;Slovakia;Spain;Costa Rica;Ukraine;Turkey;Israel;Russian Federation;United Kingdom;Ital ...

First Previous1 2 3 4 5…45Next Last